Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6853834 | 0.98 | EPHX1 (0.38) | EPHX1SIGMAR1 | |
| SCHEMBL6849211 | 0.98 | EPHX1 (0.38) | EPHX1SIGMAR1 | |
| SCHEMBL6308810 | 0.94 | EPHX1 (0.41) | EPHX1SIGMAR1 | |
| SCHEMBL6849092 | 0.89 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL5145381 | 0.89 | EPHX1 (0.31) | EPHX1 | |
| SCHEMBL6854620 | 0.85 | EPHX1 (0.44) | EPHX1SIGMAR1 | |
| SCHEMBL2636109 | 0.85 | EPHX1 (0.44) | EPHX1SIGMAR1 | |
| SCHEMBL18284382 | 0.85 | EPHX1 (0.44) | EPHX1SIGMAR1 | |
| SCHEMBL10704158 | 0.85 | EPHX1 (0.33) | EPHX1 | |
| SCHEMBL8100475 | 0.83 | CA12 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538100-B2 | 17α-alkyl-17β-oxy-estratrienes and intermediate products for their production, use of the 17α-alkyl-17β-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-05-26 | — | — | US | disclosed |
| EP-1448591-B1 | 17ALPHA-ALKYL-17BETA-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17ALPHA-ALKYL-17BETA-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | BAYER SCHERING PHARMA AG (DE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1916254-A2 | 17alpha-alkyl-17beta-oxy-estratriene and intermediates for its production, use of 17alpha-alkyl-17beta-oxy-estratriene for manufacturing medicine and pharmaceutical preparations | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-7018994-B2 | 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION, USE OF THE 17α-ALKYL-17β-OXY-ESTRATRIENES FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS AS WELL AS PHARMACEUTICAL PREPARATIONS | SCHERING AG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-01-12 | — | — | US | disclosed |
| EP-1448591-A1 | 17ALPHA-ALKYL-17BETA-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17ALPHA-ALKYL-17BETA-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | Schering Aktiengesellschaft (DE) | 2004-08-25 | — | — | EP | disclosed |
| US-6780855-B2 | TREATING A PATIENT SUFFERING FROM AN ESTROGEN DEPENDENT-DISEASE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-08-24 | — | — | US | disclosed |
| US-6677324-B1 | MIXTURE INCLUDES 7A-(E-AMINOALKYL)-ESTRATRIENE; HORMONE REPLACEMENT THERAPY; MENOPAUSE | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-13 | — | — | US | disclosed |
| US-20030191099-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | SCHERING AG (DE) | 2003-10-09 | — | — | US | disclosed |
| WO-2003045972-A1 | 17α-ALKYL-17β-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17α-ALKYL-17β-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-06-05 | — | — | WO | disclosed |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-10 | — | — | US | disclosed |
| EP-1042355-B1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | disclosed |
| EP-1054676-A1 | COMBINATION PREPARATION OF ESTROGEN AND ANTI-ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-29 | — | — | EP | disclosed |
| EP-1042355-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | Schering Aktiengesellschaft (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999042109-A1 | COMBINATION PREPARATION OF ESTROGEN AND ANTI-ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-08-26 | — | — | WO | disclosed |
| WO-1999033855-A1 | 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, METHOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009436-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | EPHX1 369/4885SIGMAR1 908/4885 |
| US-20030191099-A1 | 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations | CYP19A1, HSD17B11, CYP17A1 | EPHX1 323/4885SIGMAR1 963/4885 |
| US-20030069434-A1 | 11BETA-HALOGEN-7ALPHA-SUBSTITUTED ESTRATRIENES, METOD FOR PRODUCING PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11BETA-HALOGEN-7ALPHA- SUBSTITUTED ESTRATRIENES AND USE OF THE SAME FOR PRODUCING MEDICAMENTS | CYP19A1, HSD17B11, NR5A1 | EPHX1 409/4885SIGMAR1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.